Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes.

Roberto VisentinMichele SchiavonBritta GöbelMichela RizClaudio CobelliThomas KlabundeChiara Dalla Man

Published in: Diabetes, obesity & metabolism (2019)

After 28 days of treatment, SAR425899 improved postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate.

Keyphrases

blood glucose
type diabetes
glycemic control
cardiovascular disease
insulin resistance
metabolic syndrome
combination therapy
smoking cessation